An exhaustive study conducted by researchers at the Kaiser Permanente Division of Research has found that a woman’s social network can significantly affect her chances of survival following breast cancer.
An exhaustive study conducted by researchers at the Kaiser Permanente Division of Research, Oakland, California, has found that a woman’s social network can significantly affect her chances of survival following breast cancer.
Â
The study included more than 9000 women with breast cancer who were a part of the After Breast Cancer Pooling Project, and included women diagnosed with stages 1 to 4 invasive breast cancer. Data was collected and analyzed from breast cancer survivorship studies conducted in California, Utah, Oregon, Arizona, Texas, and Shanghai, China. Researchers examined how a range of lifestyle factors–including exercise, diet, weight management, and social factors–affect breast cancer survivorship. The study authors gathered data on social networks from these women within 2 years of their diagnosis. A social network index was derived for each participant using information such as the presence of a spouse/partner, religious ties, community ties, friendship ties, and numbers of living first-degree relatives. Stratification was by demographic, social, tumor, and treatment factors.
Â
Over a median follow-up of 10.6 years, 1448 cancer recurrences and 1521 deaths (990 from breast cancer) were documented. Compared with socially integrated women, socially isolated women had:
Of note, the associations were stronger in those with early-stage (1 or 2) cancer. Additionally, specific associations differed by age, race/ethnicity, and country of origin. For example, ties to relatives and friends predicted lower breast cancer—specific mortality in non-white women, whereas having a spouse predicted lower breast cancer—specific mortality in older white women. Ties within the community predicted better outcomes in older whites and those of Asian origin.
Â
“It is well established that larger social networks predict lower overall mortality in healthy populations and in breast cancer patients, but associations with breast cancer—specific outcomes like recurrence and breast cancer mortality have been mixed,” said lead author Candyce H. Kroenke, ScD, MPH, a research scientist with the Kaiser Permanente Northern California Division of Research. “Our findings demonstrate the beneficial influence of women's social ties on breast cancer—specific outcomes, including recurrence and breast cancer death.”
Â
Kroenke added that clinicians should assess information on social networks as a marker of prognosis and should consider that critical supports may differ by sociodemographic factors.
“Ultimately, this research may be able to help doctors tailor clinical interventions regarding social support for breast cancer patients based on the particular needs of women in different sociodemographic groups,” she said.
Â
Reference
Post-diagnosis social networks and breast cancer mortality in the After Breast Cancer Pooling Project [published online December 12, 2016]. Cancer. doi: 10.1002/cncr.30440.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More